The developing prostate has the highest rate of cell proliferation which subsequently ceases in the mature adult, resulting in a growth quiescent gland. We have focused on the morphogenesis of the mouse dorsal prostatic lobes and have identified proteins by mass spectrometry in the developing 4 week prostate that are absent in the mature 10 week prostate. These proteins will be characterized further and those which meet the criteria that they are: 1) expressed during normal prostate development in the 4 week old prostate, 2) absent in the 10 week growth quiescent prostate, 3) regulated by androgens, 4) continue to be expressed in the LPB-Tag model for prostate cancer and 5) epithelial cell specific will be utilized to develop novel models for prostate cancer. We have the composite probasin promoter (ARR2PB) which is prostate epithelial cell specific and which targets high levels of transgene expression to the mouse prostate. The transgenic mouse models will allow us to analyze the effects of over-expressing these endogenous proteins on the growth and differentiation of the normal prostate gland and to determine their role in the development of prostate cancer. Our HYPOTHESIS is that proteins that regulate normal prostate morphogenesis may promote the development of prostate cancer.
The Specific Aims of this proposal are:
Specific Aim I. To characterize the proteins previously identified in the growing 4 week prostate which are absent in the 10 week growth quiescent prostate.
Specific Aim II. To define the expression of these proteins in the developing prostate and determine whether they are re-expressed in prostate cancer (using the LPB-Tag model for prostate cancer).
Specific Aim III. To determine the function of these proteins in prostate tumorigenesis using the transgenic mouse model.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK059142-03
Application #
6752042
Study Section
Special Emphasis Panel (ZRG1-UROL (01))
Program Officer
Hoshizaki, Deborah K
Project Start
2002-07-15
Project End
2007-05-31
Budget Start
2004-06-01
Budget End
2005-05-31
Support Year
3
Fiscal Year
2004
Total Cost
$280,483
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Surgery
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Williams, Karin; Motiani, Karan; Giridhar, Premkumar Vummidi et al. (2013) CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood) 238:324-38
Williams, Karin; Ghosh, Ritwik; Giridhar, Premkumar Vummidi et al. (2012) Inhibition of stathmin1 accelerates the metastatic process. Cancer Res 72:5407-17
Chaurand, Pierre; Rahman, Mohammad A; Hunt, Tamela et al. (2008) Monitoring mouse prostate development by profiling and imaging mass spectrometry. Mol Cell Proteomics 7:411-23
Tillman, J Erin; Yuan, Jialing; Gu, Guangyu et al. (2007) DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells. Cancer Res 67:4630-7
Ghosh, Ritwik; Gu, Guangyu; Tillman, Erin et al. (2007) Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. Prostate 67:1038-52
Gu, Guangyu; Yuan, Jialing; Wills, Marcia et al. (2007) Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 67:4807-15
Pitkanen-Arsiola, Tiina; Tillman, J Erin; Gu, Guangyu et al. (2006) Androgen and anti-androgen treatment modulates androgen receptor activity and DJ-1 stability. Prostate 66:1177-93
Kasper, Susan; Cookson, Michael S (2006) Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am 33:201-10, vii
Kasper, Susan; Smith Jr, Joseph A (2004) Genetically modified mice and their use in developing therapeutic strategies for prostate cancer. J Urol 172:12-9